Stockscreener 앱 받기
27.84
0.40%
0.11
시간 외 거래:
27.84
전일 마감가:
$27.73
열려 있는:
$27.69
하루 거래량:
942.69K
Relative Volume:
0.69
시가총액:
$2.85B
수익:
$70.85M
순이익/손실:
$-324.22M
주가수익비율:
-7.3138
EPS:
-3.8065
순현금흐름:
$-277.36M
1주 성능:
-2.01%
1개월 성능:
-0.93%
6개월 성능:
+43.28%
1년 성능:
+80.43%
1일 변동 폭
$27.18
$28.14
1주일 범위
$27.00
$29.86
52주 변동 폭
$9.90
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
27.84 | 2.83B | 70.85M | -324.22M | -277.36M | -3.8065 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 재확인 | Wedbush | Outperform |
| 2025-12-03 | 개시 | William Blair | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics Hits Day High with Strong 7.14% Intraday Surge - Markets Mojo
Setup Watch: What are the future prospects of Viridian Therapeutics IncWeekly Investment Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Dow Update: Will Viridian Therapeutics Inc outperform its industry peers2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc. - MarketBeat
How Viridian Therapeutics Inc. stock responds to policy changesMarket Growth Report & Advanced Technical Analysis Signals - mfd.ru
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Earnings Beat: Is Viridian Therapeutics Inc subject to activist investor interestGap Up & Low Risk Investment Opportunities - baoquankhu1.vn
VRDN: Wedbush Reiterates 'Outperform' Rating with $44 Target | V - GuruFocus
Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront - MSN
(VRDN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RBC Capital lowers its price target on Viridian Therapeutics, Inc. (VRDN) to $42 and maintains an outperform rating - MSN
Viridian Therapeutics (VRDN) CFO amends Form 4 for tax-share disposal - Stock Titan
Viridian (VRDN) COO adjusts 3,048-share tax withholding in Form 4 amendment - Stock Titan
Viridian Therapeutics (VRDN) legal chief updates tax share disposition - Stock Titan
Viridian Therapeutics (NASDAQ: VRDN) CEO amends Form 4 tax sale - Stock Titan
Analyst Upgrade: Can Viridian Therapeutics Inc be the next market leader2026 Weekly Recap & Consistent Profit Alerts - baoquankhu1.vn
Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion By Investing.com - Investing.com Canada
Published on: 2026-03-07 18:48:40 - baoquankhu1.vn
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Volume Recap: Can Viridian Therapeutics Inc withstand a market correctionJuly 2025 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Can Viridian Therapeutics Inc stock double in the next yearEarnings Beat & Community Trade Idea Sharing Platform - baoquankhu1.vn
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating - Finviz
Vanguard Group Inc. Has $93.48 Million Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (VRDN) CEO awarded 559,600 stock options and new RSUs - Stock Titan
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia
[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan
VRDN (NASDAQ: VRDN) Form 144: proposed sale of 1,675 vested shares - Stock Titan
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC - MarketBeat
Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Biotech Powerhouse with 38% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Valuation After Wider Q4 Loss And Ongoing Thyroid Eye Disease Regulatory Reviews - simplywall.st
Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration - Sahm
What analyst consensus says on Viridian Therapeutics Inc. stockRisk Management & Free Growth Oriented Trading Recommendations - mfd.ru
How (VRDN) Movements Inform Risk Allocation Models - Stock Traders Daily
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics (VRDN) Analyst Maintains Rating; Adjusts P - GuruFocus
RBC Adjusts Price Target on Viridian Therapeutics to $42 From $45, Maintains Outperform Rating - marketscreener.com
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders - Yahoo Finance
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO) - The Globe and Mail
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026 - Meyka
VRDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):